Company intelligence / Profile preview

GPCR Therapeutics

Seoul, South Korea

Ownership: Private
Employees: ~18
Development stage: Phase 2

Overview

Interim Phase 2 data from combination therapy of GPC‑100 plus propranolol showed promising efficacy signals with good safety profiles. Inhibition of both CXCR4 and B2AR enhanced chemotherapy efficacy significantly (>10-fold increase reported). The trial aims to complete dosing by April with results expected September/July follow-up analysis planned.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

burixafor + propranolol

Phase 2

Indications: Multiple myeloma

Partnerships

Exicure Inc.Australian biotech AdAlta ASX:1AD

Beyond the preview

Go deeper on GPCR Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPCR Therapeutics.

Explore the full profile